LAAO stands for left atrial appendage occlusion, a procedure that seals off a small pouch in the heart to prevent strokes in people with atrial fibrillation. It’s designed as an alternative to long-term blood thinners for patients who can’t safely take those medications. The procedure works by closing the opening to the left atrial appendage (LAA), a finger-shaped sac in the upper left chamber of the heart where dangerous blood clots tend to form.
Why the Left Atrial Appendage Matters
The left atrial appendage is a remnant of the embryonic heart. In healthy people, it actively contracts, helps regulate pressure in the heart, and produces a hormone involved in fluid balance. But in people with atrial fibrillation, the heart’s upper chambers quiver instead of pumping effectively, and blood can pool inside the LAA. That stagnant blood is prone to clotting.
The LAA is responsible for the vast majority of stroke-causing clots in people with AFib. In one study of 317 AFib patients who had recently experienced a stroke or similar event, about 20% had a visible clot in the heart, and every single one was located in the LAA. A larger analysis of nearly 4,800 AFib patients found clots in about 14% of them, with the LAA as the source in most cases. The slower blood flows through the appendage, the higher the risk: people who formed clots had average flow speeds less than half those of people who didn’t.
Structural changes matter too. Scarring (fibrosis) inside the appendage walls slows blood flow further, and more complex internal ridges within the LAA are independently linked to higher stroke risk. All of this makes the LAA the primary target for stroke prevention beyond medications.
Who Is a Candidate
LAAO isn’t a first-line treatment for everyone with AFib. It’s specifically aimed at people who have a meaningful stroke risk but can’t safely take blood thinners long term. Medicare coverage guidelines require that a patient have non-valvular atrial fibrillation (meaning no significant heart valve disease), a high stroke risk score, a high bleeding risk score, and a specific reason they can’t tolerate anticoagulant medications. That reason might be a history of serious bleeding, frequent falls, kidney problems that make blood thinners dangerous, or side effects severe enough to force discontinuation.
In practice, the typical LAAO candidate is an older adult with multiple health conditions who faces a real dilemma: they need stroke protection, but blood thinners pose too great a bleeding risk. The procedure offers a way out of that tradeoff.
How the Procedure Works
LAAO is a catheter-based procedure, meaning it doesn’t require open-heart surgery. You’re placed under general anesthesia, and the cardiologist threads a thin tube (catheter) through a vein in your groin up to the heart. To reach the left side of the heart, the catheter passes through the wall separating the two upper chambers, a step called transseptal puncture. The doctor uses X-ray imaging and sometimes ultrasound guidance to position the catheter precisely at the opening of the LAA.
Once in position, a small plug-like device is deployed to seal the appendage. The device expands to fit the shape of your LAA, blocking blood from entering or leaving the pouch. The doctor confirms proper placement and checks for leaks using imaging before releasing the device permanently. The whole procedure typically takes about an hour.
Two devices are currently FDA-approved for this purpose: the Watchman (made by Boston Scientific) and the Amulet (made by Abbott). Both work on the same principle, though they differ slightly in design. The Watchman FLX, the newer generation of the Watchman, achieves a successful seal in about 98.6% of cases, with complete closure confirmed by imaging in over 97% of patients.
What Recovery Looks Like
Most people go home the day after the procedure. Because the device needs time to become fully incorporated into the heart tissue, a process called endothelialization, you’ll take some form of blood-thinning or antiplatelet medication for a limited period afterward. For high-bleeding-risk patients, this is often antiplatelet therapy alone for six months or less, after which many patients stop all blood-thinning medications entirely. That complete cessation is the ultimate goal and one of the main appeals of the procedure.
At around 45 days post-procedure, you’ll have a follow-up imaging study, typically a transesophageal echocardiogram (a specialized ultrasound taken from the esophagus, which sits right behind the heart). This confirms the device is stable, checks for any clot formation on the device surface, and looks for leaks around the edges. If results are equivocal, a CT scan can provide additional detail. The small hole made in the wall between the upper chambers during the procedure usually closes on its own and is checked during this same imaging visit.
How Well It Prevents Strokes
A comprehensive meta-analysis comparing LAAO devices to oral anticoagulants found that the two strategies are essentially equivalent at preventing the most common type of stroke (ischemic stroke caused by a clot). Where LAAO showed a clear advantage was in reducing hemorrhagic stroke, the type caused by bleeding in the brain, by 59%. This makes sense: once the device is in place and medications are stopped, there’s no ongoing bleeding risk from blood thinners. LAAO also reduced transient ischemic attacks (brief stroke-like episodes) by 28% compared to anticoagulants.
Most of the comparison data involves warfarin rather than newer blood thinners like apixaban or rivarelbaan, so direct comparisons with those newer drugs are still limited. But even newer anticoagulants carry some bleeding risk that a successfully implanted device eliminates.
Risks and Complications
Like any heart procedure, LAAO carries some upfront risk. The most common complication is pericardial effusion, fluid accumulating around the heart, which occurs in roughly 3.4% of cases. About 1.2% of patients need that fluid drained. Bleeding requiring a transfusion happens in about 1.4% of procedures. Device embolization, where the plug dislodges and travels through the bloodstream, is extremely rare at about 0.02%.
These are procedural risks, meaning they occur during or shortly after the implant. Once the device has healed into the tissue and medications are discontinued, the ongoing risk profile is favorable. The key tradeoff is accepting a small one-time procedural risk in exchange for eliminating the continuous daily bleeding risk that comes with lifelong anticoagulation.